Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06926582
PHASE2

A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

Sponsor: Hansoh BioMedical R&D Company

View on ClinicalTrials.gov

Summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.

Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Clinical Efficacy and Safety of HS-10374 in Adult Patients With Mild-to-moderate Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

305

Start Date

2025-04-09

Completion Date

2026-12-09

Last Updated

2025-04-13

Healthy Volunteers

No

Conditions

Interventions

DRUG

HS-10374 6mg tablets

Administered orally QD for 12 weeks

DRUG

HS-10374-matched placebo tablets

Administered orally QD for 12 weeks

Locations (1)

Shanghai Dermatology Hospital

Shanghai, Shanghai Municipality, China